ALLIANCE FOR AGING RESEARCH for ALLIANCE FOR AGING RESEARCH
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 16, 2026 | $70,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Jul 16, 2026 | $70,000 | Replaced |
| 2nd Quarter - Amendment | Sep 24, 2026 | $70,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
-FY27 report language for the Food and Drug Administration on antipsychotics black box warning -FY27 report language for the Medicare Program antipsychotics measure -FY27 report language for the Medicare Prescription Payment Plan -FY27 report language for utilization management reform in the Medicare program -FY27 medical research funding -FY27 funding for FDA's Neurology Drug Program -FY 27 Appropriations H.R. 9260 and pending Senate bill, Increase Funding for Programs benefitting older adults at HHS, including ASPE, NIH, CDC HRSA, ARHQ, FDA, CMS, ACL
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT FREY | Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy |
| ADINA ROSE LASSER | — |
Health Issues HCR
-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants -Clinical Trials Modernization Act H.R.7905 -Patient Access to Cancer and Complex Therapies Act H.R. 4299 -Diabetes Foot Health and Modernization Access Act H.R. 7905 -Oppose PBM Kickbacks H.R. 7895 -Oppose Codification of MFN Drug Pricing Proposals (no bill) -End Coverage with Evidence Development for Alzheimer's medications and Trans Catheter Aortic Valve Replacement
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT FREY | Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy |
| ADINA ROSE LASSER New | — |
Medicare/Medicaid MMM
-Implementation of Medicare Part D beneficiary affordability provisions -Nursing home quality measures -Implementation of the Medicare Direct Negotiation Program and its impact on older adults -Utilization management reform in Medicare -Increasing Medication Access for Seniors Act (H.R.6401) -End Coverage with Evidence Development for Alzheimer's Medications and TAVR
| Lobbyist | Covered position, as disclosed |
|---|---|
| SCOTT FREY New | Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy |
| ADINA ROSE LASSER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.